All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb and Incyte. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Jean-Jacques KiladjianDuring the 49th Annual Meeting of the EBMT, the MPN Hub was pleased to speak to Jean-Jacques Kiladjian, Université de Paris - Hôpital Saint-Louis, Paris, FR. We asked, Is transplantation still the only curative treatment for myelofibrosis (MF)?
Is transplantation still the only curative treatment for MF?
In this interview, Kiladjian outlines the many obstacles to curing MF including the dynamic nature of driver mutations and the limited therapy options currently available. Moving forward, Kiladjian goes on to review emerging treatments that may be used in combination with existing therapies to achieve a potentially curative result in the future. Kiladjian concludes by discussing the indications and key safety considerations for the use of transplantation in MF.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content